<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of hemolytic uremic syndrome in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of hemolytic uremic syndrome in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of hemolytic uremic syndrome in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Olivia Gillion Boyer, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H12590497"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The hemolytic uremic syndrome (HUS) is defined by the simultaneous occurrence of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury [<a href="#rid1">1</a>]. It is one of the main causes of acute kidney injury in children. Although all pediatric cases exhibit the classic triad of findings that define HUS, there are a number of various etiologies of HUS that result in differences in presentation, management, and outcome.</p><p>This topic will provide an overview of the different causes, evaluation, and initial management of HUS in children. HUS in adults is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/114693.html" rel="external">"Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS"</a>.)</p><p class="headingAnchor" id="H1843666411"><span class="h1">DEFINITIONS</span></p><p>Thrombotic microangiopathy describes a specific pathologic lesion in which abnormalities in the vessel wall of arterioles and capillaries lead to microvascular thrombosis. It includes several primary disorders including thrombotic thrombocytopenic purpura, Shiga toxin-mediated HUS and complement-mediated HUS or TMA. (See  <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a>.) </p><p class="headingAnchor" id="H12590511"><span class="h2">Classification</span><span class="headingEndMark"> — </span>In the past, HUS had been divided into diarrhea-positive and diarrhea-negative HUS. The former, also referred to as typical HUS, primarily resulted from Shiga toxin-producing Escherichia coli (STEC) infections, and less frequently from Shigella dysenteriae type 1 infection. All other causes of HUS were referred to as atypical HUS or assigned to the diarrhea-negative HUS, even though some patients with non-STEC-associated HUS also presented with diarrhea.</p><p>However, ongoing research has provided a better understanding of the underlying causes of HUS, especially those due to genetic mutations in the alternative pathway of complement [<a href="#rid2">2,3</a>]. As a result, the following classification has been developed based on pathophysiological considerations and triggering factors [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary causes of HUS [<a href="#rid5">5</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complement gene mutations (see  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inborn errors of cobalamin C metabolism (see <a class="local">'Cobalamin C'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diacylglycerol kinase epsilon (DGKE) gene mutations (see <a class="local">'Coagulation pathway'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acquired causes of HUS:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infection:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Shiga toxin-producing Escherichia coli (STEC) (see  <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">"Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Streptococcus pneumoniae (see <a class="local">'Streptococcus pneumoniae'</a> below)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Human immunodeficiency viral infection</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autoantibodies to complement factors</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Drug toxicity, particularly in patients with cancer or solid organ transplant recipients</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rare occurrences in pregnant patients or those with autoimmune disorders (eg, systemic lupus erythematous)</p><p></p><p class="headingAnchor" id="H12593928"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Shiga toxin-producing E. coli hemolytic uremic syndrome (STEC HUS) is the most common cause of pediatric HUS, accounting for 90 percent of cases [<a href="#rid6">6</a>]. It primarily affects children under the age of five years. In the United States and Western Europe, the reported annual incidence of STEC HUS is approximately two to three per 100,000 children less than five years of age [<a href="#rid1">1</a>]. The remaining childhood HUS cases are generally divided into primary HUS caused by complement dysregulation, with an estimated prevalence of seven per one million children in Europe [<a href="#rid7">7</a>], and secondary HUS caused by pneumococcal infection [<a href="#rid8">8,9</a>].</p><p class="headingAnchor" id="H368186215"><span class="h1">HEREDITARY HUS</span></p><p class="headingAnchor" id="H4246740349"><span class="h2">Complement gene mutations</span><span class="headingEndMark"> — </span>Complement-mediated hemolytic uremic syndrome (HUS) is primarily due to mutations in the genes for complement proteins C3, CD46 (previously known as membrane cofactor protein [MCP]), and complement factors H, B, and I. It is estimated that approximately 50 percent of non-Shiga toxin-producing E. coli (STEC) cases result from mutations in these genes [<a href="#rid10">10,11</a>]. The clinical manifestation, diagnosis, evaluation, and management of complement-mediated HUS are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children"</a>.)</p><p class="headingAnchor" id="H709624363"><span class="h2">Mutations in non-complement genes</span></p><p class="headingAnchor" id="H1600990335"><span class="h3">Coagulation pathway</span><span class="headingEndMark"> — </span>Mutations in genes coding for proteins involved in the coagulation pathway have been reported in patients with atypical HUS.</p><p class="bulletIndent1"><span class="glyph">●</span><em>DGKE</em> mutations – Recessive mutations in <em>DGKE</em> (encoding diacylglycerol kinase epsilon) were identified in nine unrelated kindreds with atypical HUS [<a href="#rid12">12</a>]. The authors suggest loss of <em>DGKE</em> function results in a prothrombotic state as DGKE inactivates arachidonic acid-containing diacylglycerols (DAG), an activator of protein kinase C, which promotes thrombosis. In one consanguineous family with a novel truncating mutation in <em>DGKE</em> (p.K101X), patients showed significant complement activation and low C3 levels. Aggressive plasma infusion therapy controlled systemic symptoms and prevented renal failure [<a href="#rid13">13</a>]. Another study of four patients with <em>DGKE</em> mutations found that three of them also carried heterozygous mutations in thrombomodulin (<em>THBD</em>) or <em>C3</em> [<a href="#rid14">14</a>]. Plasma therapy was effective in two patients with <em>DGKE</em> and <em>THBD</em> mutations, while plasma infusions and <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> were effective in the patient with <em>DGKE</em> and <em>C3</em> mutations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>PLG</em> mutations – A comprehensive genetic analysis of complement and coagulation genes in patients with atypical HUS detected not only mutations in complement regulatory genes in over one-half of the patients, but also novel mutations in several genes in the coagulation system, particularly ones in the <em>PLG </em>gene, which encodes plasminogen [<a href="#rid15">15</a>]. Plasminogen deficiency results in a decreased degradation of thrombi, promoting thrombosis. The authors speculate that thrombi in small vessels cause mechanical damage to erythrocytes, releasing peptides (such as heme), or overexpression of other unidentified factors that activate the complement system, resulting in endothelial cell damage and HUS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombomodulin mutations – Thrombomodulin is a cofactor in the initiation of the protein C anticoagulant pathway, which accelerates the inactivation of C3b by factor I. In a study of 152 patients with atypical HUS (ie, non-Shiga toxin-producing <em>E. coli</em> [STEC]-HUS), seven patients had six different heterozygous mutations of the <em>THBD</em> gene [<a href="#rid16">16</a>]. In vitro studies demonstrated that the mutated <em>THBD</em> gene resulted in dysregulation of the complement system because it was less effective than normal thrombomodulin in converting C3b to its inactive form iC3b. (See  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children"</a>.)</p><p></p><p class="headingAnchor" id="H1143163617"><span class="h3">Cobalamin C</span><span class="headingEndMark"> — </span>A majority of patients with mutations in the <em>MMACHC </em>(MethylMalonic ACiduria and Homocystinuria type C) gene, which results in methylmalonic aciduria and homocystinuria, are diagnosed with atypical HUS. Mutations of <em>MMACHC</em> result in functional cobalamin (vitamin B12) deficiency. Cobalamin is a cofactor for both methionine-synthase, which transforms homocysteine to methionine, and methyl-transferase, which is involved in the conversion of methylmalonyl CoA to succinyl CoA [<a href="#rid17">17</a>]. As a result, patients with CblC mutations have a functional defect of both methylmalonyl CoA mutase and methionine synthase resulting in methylmalonic acidemia with homocystinuria.</p><p>Clinical manifestations are characterized by marked heterogeneity of neurocognitive disease (microcephaly, seizures, developmental delay, ataxia, hypotonia) and a diagnosis of atypical HUS in a majority of patients [<a href="#rid18">18</a>]. The first symptoms, which are nonspecific, may occur in the neonatal period and consist of anorexia, vomiting, failure to thrive, hypotonia, seizures, and lethargy [<a href="#rid19">19,20</a>]. In these patients, symptoms of HUS are typically severe and observed beyond infancy. The prognosis is poor due to multiorgan failure. Later-onset forms presenting with psychiatric/behavior problems and myelopathy have been reported with better prognosis [<a href="#rid21">21-23</a>]. The diagnosis, which should be suspected in the presence of megaloblastosis, is made by amino acid and organic acid chromatography that reveal a marked increase of homocysteine and a low level of methionine in the plasma, and very high rates of urinary excretion of homocysteine and methylmalonic acid and by genetic testing of the <em>MMACHC</em> gene. Therapy should be started as soon as possible and includes parenteral administration of <a class="drug drug_pediatric" data-topicid="13365" href="/z/d/drug information/13365.html" rel="external">hydroxocobalamin</a>, <a class="drug drug_pediatric" data-topicid="13041" href="/z/d/drug information/13041.html" rel="external">betaine</a>, <a class="drug drug_pediatric" data-topicid="13119" href="/z/d/drug information/13119.html" rel="external">carnitine supplements</a>, and <a class="drug drug_pediatric" data-topicid="12544" href="/z/d/drug information/12544.html" rel="external">leucovorin</a> calcium, as early initiation of treatment improves prognosis [<a href="#rid20">20,24,25</a>]. (See  <a class="medical medical_review" href="/z/d/html/2927.html" rel="external">"Organic acidemias: An overview and specific defects", section on 'Methylmalonic acidemia'</a>.) </p><p class="headingAnchor" id="H12590518"><span class="h1">ACQUIRED INFECTIOUS-INDUCED HUS</span></p><p class="headingAnchor" id="H19598446"><span class="h2">Shiga toxin-producing E. coli (STEC)</span><span class="headingEndMark"> — </span>As noted above, Shiga toxin-producing E. coli (STEC) hemolytic uremic syndrome (HUS) accounts for over 90 percent of cases of HUS in children. It is generally preceded by a prodromal illness with abdominal pain, vomiting, and diarrhea, which is usually bloody  (<a class="graphic graphic_figure graphicRef75352" href="/z/d/graphic/75352.html" rel="external">figure 1</a>). The clinical manifestations, diagnosis, evaluation, and management of STEC HUS are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">"Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"</a> and  <a class="medical medical_review" href="/z/d/html/6097.html" rel="external">"Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"</a>.)</p><p class="headingAnchor" id="H12590526"><span class="h2">Streptococcus pneumoniae</span></p><p class="headingAnchor" id="H19598557"><span class="h3">Epidemiology</span><span class="headingEndMark"> — </span>Pneumococcal-associated hemolytic uremic syndrome (HUS) has been reported in 5 to 15 percent of all childhood cases of HUS, and in 40 percent of non-STEC HUS cases [<a href="#rid8">8,9</a>]. Pneumococcal-associated HUS occurs mainly in infants and young children, and rarely affects adults. The incidence of HUS after pneumococcal disease is about 0.5 percent. An analysis of the Kids' Inpatient Database reported pneumococcal-associated HUS accounted for 4.6 percent of all HUS discharges, 0.7 percent of all invasive pneumococcal disease discharges, and 3 percent of all discharges for complicated pneumonia in the United States in 2009 [<a href="#rid26">26</a>].</p><p>After the introduction of the seven-valent pneumococcal conjugate vaccine (PCV) in 2000, the incidence of cases due to serotypes 3, 6A, 12F, and 19A, which were not covered in the vaccine, has increased [<a href="#rid9">9,27-29</a>]. In one retrospective review from a tertiary center in Australia of cases from 1997 to 2016, pneumococcal infection was identified in 11 of 66 cases of HUS, and 19A serotype was detected in six of the patients including those who received the 13-valent PCV, which covers 19A serotype [<a href="#rid28">28</a>]. In the United Kingdom, the incidence of pneumococcal-associated HUS decreased since the 2010 introduction of the 13-valent pneumococcal vaccine and cases were more likely to be due to serotypes not covered in the 13-valent pneumococcal vaccine [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/7023.html" rel="external">"<i>Streptococcus pneumoniae</i>: Microbiology and pathogenesis of infection"</a>.)</p><p class="headingAnchor" id="H12590533"><span class="h3">Pathogenesis</span><span class="headingEndMark"> — </span>Although the pathogenesis of pneumococcal-associated HUS is uncertain [<a href="#rid30">30</a>]. Proposed mechanisms include: </p><p class="bulletIndent1"><span class="glyph">●</span>Increased expression of the pneumococci surface proteins (PspC) that bind plasminogen. This results in plasmin generation resulting in fibrinogen degradation and complement activation and leads to endothelial cell damage [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complement-mediated HUS – Case reports found complement activation and consumption in some children with pneumococcal-associated HUS [<a href="#rid32">32,33</a>]. Further evaluation identified risk haplotypes and, in one individual, a pathologic complement variant that may have contributed to development of HUS triggered by pneumococcal infection in these susceptible individuals. (See  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An older hypothesis centered on a role for N-acetyl neuraminidase (sialidase) released during pneumococcal infection, which cleaves sialic acid on the cell glycocalyx. It has been proposed that desialylation by neuraminidase results in exposing Thomsen-Friedenreich antigen (T antigen) on red blood cells, platelets and glomeruli resulting in polyagglutination of patients' red cells and hemolysis [<a href="#rid34">34</a>]. However, subsequent observations argue against a pathogenetic role for the T antigen [<a href="#rid34">34,35</a>]. An alternative proposal is desialylation by neuraminidase disrupting complement factor H (complement regulatory protein) binding sites, which would result in the inability of complement factor B to bind with C3 convertase resulting in unregulated complement activation similar to what is seen in patients with hereditary HUS due to complement gene mutations. (See  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Pathogenesis'</a>.)</p><p></p><p class="headingAnchor" id="H19598564"><span class="h3">Clinical manifestations</span><span class="headingEndMark"> — </span>Patients with pneumococcal-associated HUS typically present with pneumonia (70 percent), which is usually accompanied by empyema or effusion [<a href="#rid9">9,36</a>]. Meningitis is the second most common presentation, occurring in approximately 20 to 30 percent of cases. Other pneumococcal infections associated with HUS include isolated bacteremia, sinusitis, and otitis media.</p><p>Children with pneumococcal-associated HUS compared with those with STEC HUS are younger (median age between one and two years of age), have more severe initial disease with longer duration of oliguria and thrombocytopenia, and require more transfusions [<a href="#rid37">37</a>]. In two case series, 70 to 80 percent of patients underwent dialysis therapy [<a href="#rid9">9,36</a>]. Extra-renal complications are also common and include pancreatitis, purpura fulminans, cholecystitis, thrombosis, cardiac dysfunction, and hearing loss [<a href="#rid36">36,37</a>].</p><p class="headingAnchor" id="H90806153"><span class="h3">Management</span><span class="headingEndMark"> — </span>The management of pneumococcal-associated HUS is generally supportive (see <a class="local">'Treatment'</a> below). In addition, empiric antibiotic therapy for invasive pneumococcal disease should be initiated while awaiting culture results and sensitivities. Because of the increasing prevalence of antibiotic-resistant strains of pneumococcus, and generally due to the severity of the underlying infection, coverage should include both <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> and a broad-spectrum cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> or <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a>). (See  <a class="medical medical_review" href="/z/d/html/6060.html" rel="external">"Pneumococcal pneumonia in children", section on 'Empiric therapy'</a>.)</p><p>Many experts in the field avoid plasma infusion or plasmapheresis because of concerns that plasma, which contains natural IgM class antibodies to the T antigen, may aggravate hemolysis. However, this has not been proven, and seems unlikely given that these antibodies are active at 4°C and not at 37°C (body temperature). It has also been suggested that blood products should be washed to prevent administration of additional anti-T antigen antibodies [<a href="#rid37">37</a>].</p><p>It is uncertain whether <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a>, a monoclonal antibody C5 inhibitor, is beneficial. In one of the previously mentioned case reports of complement activation in children with pneumococcal-associated HUS, eculizumab appeared to be beneficial in two of the three patients who received this therapy [<a href="#rid33">33</a>]. In the third patient, eculizumab was discontinued due to severe infection. The use of eculizumab in patients with complement-mediated HUS is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Complement blockade (eculizumab)'</a>.)</p><p class="headingAnchor" id="H19598644"><span class="h3">Outcome</span><span class="headingEndMark"> — </span>Patients with pneumococcal-associated HUS have a higher mortality and long-term morbidity rate than those with STEC disease. In a review of the literature of pneumococcal-associated cases of HUS through 2008, the mean mortality rate was 12 percent, 10 percent of patients progressed to end-stage renal disease (ESRD), and 16 percent survived with chronic kidney disease [<a href="#rid38">38</a>].</p><p>The cause of death is typically due to the underlying infection. In a case series of 43 patients from the United Kingdom, there were five deaths that were due to meningitis (n = 3), sepsis (n = 1), and pulmonary emboli while on hemodialysis (n = 1) [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H12590540"><span class="h2">HIV infection</span><span class="headingEndMark"> — </span>HUS or thrombotic thrombocytopenic purpura (TTP) has been observed in patients, including children, with human immunodeficiency virus (HIV) infection [<a href="#rid39">39</a>]. The majority of affected patients progress to end-stage renal disease (ESRD). The incidence of HUS associated HIV infection has decreased after the introduction of retroviral therapies. HIV-associated TTP and HUS are discussed separately.</p><p class="headingAnchor" id="H90806194"><span class="h2">H1N1 influenza A</span><span class="headingEndMark"> — </span>Several case reports have been published concerning the development of HUS in patients with H1N1 influenza A infection [<a href="#rid40">40-48</a>]. However, it should be remembered that Streptococcus pneumoniae infection is a frequent secondary bacterial infection during influenza A infections. Thus, HUS may have resulted from pneumococcal disease rather than influenza infection [<a href="#rid49">49</a>]. In some patients, an underlying complement defect was observed and infection due to influenza A was considered a trigger for complement-mediated HUS [<a href="#rid45">45,48,50</a>]. (See  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Pathogenesis'</a>.)</p><p>HUS has also been reported in association with Entamoeba histolytica intestinal infection and with mycoplasma pneumoniae infections [<a href="#rid51">51,52</a>].</p><p class="headingAnchor" id="H12590610"><span class="h1">ACQUIRED NON-INFECTIOUS CAUSES</span><span class="headingEndMark"> — </span>Non-infectious secondary causes of hemolytic uremic syndrome (HUS) have been reported in the following settings [<a href="#rid53">53</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Antibodies to complement factors</p><p class="bulletIndent1"><span class="glyph">●</span>Adverse effects of medications</p><p class="bulletIndent1"><span class="glyph">●</span>Complications of specific conditions including pregnancy, systemic lupus erythematosus and antiphospholipid syndrome</p><p></p><p class="headingAnchor" id="H2631278239"><span class="h2">Antibody to complement factors</span><span class="headingEndMark"> — </span>Antibodies to complement factors B and H have been implicated as an acquired cause of HUS. (See  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Complement antibodies'</a>.) </p><p></p><p class="headingAnchor" id="H189881702"><span class="h2">Medications</span><span class="headingEndMark"> — </span>Several medications have been implicated as causes of acquired thrombotic microangiopathy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcineurin inhibitors</strong> – HUS has occurred in solid organ transplant recipients treated with calcineurin inhibitors (ie, <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a> or <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">tacrolimus</a>). Thrombotic microangiopathy (TMA)/HUS usually occurs during the first few months post-transplantation, a time when high doses of calcineurin inhibitors are being administered. Thrombotic microangiopathy with multiorgan injury may occur after hematopoietic stem cell transplantation [<a href="#rid54">54,55</a>]. (See  <a class="medical medical_review" href="/z/d/html/7350.html" rel="external">"Thrombotic microangiopathy after kidney transplantation", section on 'Epidemiology of de novo TMA'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytotoxic drugs</strong> – Among children with cancer who are treated with cytotoxic drugs, such as <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">mitomycin</a>, <a class="drug drug_pediatric" data-topicid="13088" href="/z/d/drug information/13088.html" rel="external">bleomycin</a>, <a class="drug drug_pediatric" data-topicid="13154" href="/z/d/drug information/13154.html" rel="external">gemcitabine</a>, or <a class="drug drug_pediatric" data-topicid="13162" href="/z/d/drug information/13162.html" rel="external">cisplatin</a>. Vascular endothelial growth factor (VEGF) inhibitors used as antiangiogenic therapy may be responsible for thrombotic microangiopathy/HUS [<a href="#rid55">55,56</a>]. (See  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Cancer therapies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – Other implicated medications include <a class="drug drug_pediatric" data-topicid="12756" href="/z/d/drug information/12756.html" rel="external">quinine</a>, interferon beta, and oral contraceptives. (See  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Quinine'</a>.)</p><p></p><p class="headingAnchor" id="H3055722793"><span class="h2">Other conditions</span><span class="headingEndMark"> — </span>TMA/HUS has been reported in patients with the following conditions:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiphospholipid syndrome – In children with systemic lupus erythematosus and those with a severe antiphospholipid syndrome. (See  <a class="medical medical_review" href="/z/d/html/3073.html" rel="external">"Antiphospholipid syndrome and the kidney", section on 'Kidney manifestations of antiphospholipid syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy – Pregnancy-HUS occurs mainly in the postpartum period and is most likely due to complement-mediated HUS triggered by pregnancy [<a href="#rid57">57-59</a>]. Its treatment therefore should include the use of the anti-C5 humanized monoclonal antibody <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/z/d/html/6681.html" rel="external">"Thrombocytopenia in pregnancy", section on 'Thrombotic microangiopathy (TMA)'</a> and  <a class="medical medical_review" href="/z/d/html/114693.html" rel="external">"Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS", section on 'Other disorders that present with MAHA and thrombocytopenia'</a>.)</p><p></p><p class="headingAnchor" id="H12590653"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of hemolytic uremic syndrome (HUS) is clinically based on the presence of the classical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury, which is established by laboratory tests that include a complete blood count (eg, hemoglobin and platelet count) and peripheral blood smear, renal functions studies, and urinalysis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemolytic anemia</strong> – The microangiopathic hemolytic anemia is established by a hemoglobin level less than 8 g/dL with a negative Coomb's test and a peripheral blood smear demonstrating a large number of schistocytes (up to 10 percent of red cells) and helmet cells  (<a class="graphic graphic_picture graphicRef70851" href="/z/d/graphic/70851.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef50715" href="/z/d/graphic/50715.html" rel="external">picture 2</a>). (See  <a class="medical medical_review" href="/z/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children"</a> and  <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)", section on 'Microangiopathic hemolytic anemia (MAHA)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombocytopenia</strong> – Thrombocytopenia is characterized by a platelet count below 140,000/mm<sup>3</sup> and is usually approximately 40,000/mm<sup>3</sup>. Despite the low platelet count, there is typically no purpura or active bleeding. The degree of thrombocytopenia is unrelated to the severity of renal dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute kidney injury</strong> − The severity of renal involvement ranges from hematuria and proteinuria to severe renal failure (usually identified by abnormally elevated serum creatinine and blood urea nitrogen [BUN] levels) and oligoanuria. Severe renal failure occurs in one-half of cases. Hypertension is common, particularly after the administration of excess fluids or blood transfusions. Most patients have microscopic hematuria on urinalysis, although macroscopic hematuria may be observed. Red blood cell casts are occasionally seen, but are not a typical feature.</p><p></p><p>Further evaluation including additional laboratory tests is needed to determine the underlying cause of HUS and to differentiate HUS from other disorders [<a href="#rid5">5</a>]. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H90805724"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential for hemolytic uremic syndrome (HUS) includes several conditions that may also present with concomitant findings of anemia, thrombocytopenia, and acute kidney injury.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disseminated intravascular coagulation</strong> (DIC) – DIC is distinguished from HUS by the presence of abnormal coagulation studies, including prolonged prothrombin time and activated partial thromboplastin time, and elevated levels of fibrin degradation products and D-dimer. In general, DIC occurs in pediatric patients who are seriously ill, such as those in septic shock or who have undergone massive tissue injury or breakdown. (See  <a class="medical medical_review" href="/z/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombotic thrombocytopenic purpura</strong> (TTP) – TTP is due to deficient activity of the Von Willebrand factor cleaving protease caused by mutations of the ADAMTS13 gene or to the presence of acquired anti-ADAMTS13 antibodies. Pediatric TTP is rare, and affected children usually present at birth with hemolytic anemia and thrombocytopenia. Renal involvement often occurs later in life and has a progressive course. TTP is distinguished from HUS by abnormally low ADAMTS13 activity. (See  <a class="medical medical_review" href="/z/d/html/1338.html" rel="external">"Diagnosis of immune TTP", section on 'Reduced ADAMTS13 activity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic vasculitis</strong> – Patients with vasculitis typically have other systemic symptoms (such as arthralgias and rash) and do not have a prodromal diarrheal illness. In addition, the characteristic neurologic involvement in patients with vasculitis is peripheral (eg, mononeuritis multiplex) rather than central.</p><p></p><p class="headingAnchor" id="H12590660"><span class="h1">EVALUATION TO IDENTIFY UNDERLYING ETIOLOGY</span><span class="headingEndMark"> — </span>Once the diagnosis of hemolytic uremic syndrome (HUS) is made, evaluation is focused on identifying the underlying cause of HUS and also differentiating HUS from other conditions that have similar presentations, as this may affect management decisions.</p><p class="bulletIndent1"><span class="glyph">●</span>Historical clues include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Concurrent history of HUS in a family member is suggestive of an infectious etiology, especially Shiga toxin-producing E. coli (STEC) HUS.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Past (noncurrent) history of HUS in a family member is suggestive of a genetic complement-mediated cause of HUS. (See  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Previous episode of HUS is suggestive of complement-mediated HUS. (See  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of possible exposure to STEC is suggestive of STEC HUS. This includes ingestion of undercooked ground beef or other foods that may be fecally contaminated by cattle, swimming in a potentially contaminated lake or pool, or contact with farm animals. (See  <a class="medical medical_review" href="/z/d/html/2711.html" rel="external">"Shiga toxin-producing Escherichia coli: Microbiology, pathogenesis, epidemiology, and prevention", section on 'Transmission'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Review of current medications to identify any drug that may be associated with HUS. (See <a class="local">'Medications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Review of other medical conditions that may be associated with HUS (eg, solid organ recipient, malignancy, or pregnancy). (See <a class="local">'Medications'</a> above and <a class="local">'Other conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The following laboratory studies are often obtained at the same time as initial testing, which establishes the diagnosis of HUS (ie, complete blood count and peripheral smear, renal function studies, and urinalysis). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Coagulation studies including prothrombin time, and activated partial thromboplastin time to distinguish HUS from disseminated intravascular coagulation (DIC).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Screening for Shiga toxin-producing bacterial strains to differentiate STEC HUS from other forms of HUS. This includes testing for Shiga toxins (eg, ELISA) in the stool, stool cultures, and serologic testing for IgM and anti-lipopolysaccharide antibodies against the most frequent STEC serotypes. In addition, polymerase chain reaction (PCR) testing for Shiga toxin genes can also be performed. (See  <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">"Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Testing for STEC infection'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the setting of concurrent serious infection, cultures of blood, and other tissues/organs as clinically indicated (eg, sputum, urine, stool, and cerebral spinal fluid), may detect an underlying infectious etiology for HUS, such as pneumococcal-associated HUS. In addition, critically ill patients from septic shock may also develop DIC, which may present with similar manifestations to HUS.</p><p></p><p>Based on the above evaluation, the underlying cause of HUS may be apparent. However, in some cases, further evaluation may be needed to identify the underlying cause and also to differentiate HUS from other conditions with similar manifestations [<a href="#rid5">5</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Initial complement studies include measuring complement factors 3 and 4 (C3 and C4). Low serum C3 and C4 may indicate complement-mediated HUS. However, missense mutations of complement proteins typically result in functional impairment without affecting complement protein levels. Other complement studies include serum levels of thrombomodulin and complement factors H, B, and I; CD46 leukocyte expression; and testing for antibodies to complement factor H. Definitive diagnosis of genetic complement-mediated HUS requires complement genotyping. (See  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serology for human immunodeficiency virus (HIV), and testing for systemic lupus erythematous (antinuclear antibodies and antiphospholipid antibodies). (See  <a class="medical medical_review" href="/z/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/86984.html" rel="external">"Acute and early HIV infection: Clinical manifestations and diagnosis", section on 'Diagnostic test performance in early HIV infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In some patients, in whom the diagnosis is uncertain, a renal biopsy may be performed. Renal histology typically demonstrates glomerular thrombotic microangiopathy in patients with STEC HUS, characterized by a thickening of the capillary walls, with a double-contour appearance due to a widening of the subendothelial space. In patients with complement-mediated HUS, the renal histological lesion is most often arteriolar thrombotic microangiopathy, perhaps accounting for the markedly increased blood pressure seen in these [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for defective cobalamine metabolism in neonates who present with HUS. (See <a class="local">'Acquired non-infectious causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessing ADAMTS 13 function to differentiate HUS from thrombotic thrombocytopenic purpura (TTP). (See  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Thrombotic thrombocytopenic purpura'</a>.) </p><p></p><p class="headingAnchor" id="H12590674"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H2346276742"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>The initial management of hemolytic uremic syndrome (HUS) is supportive and is based on observational data from studies of patients with Shiga toxin-producing E. coli (STEC) HUS. (See  <a class="medical medical_review" href="/z/d/html/6097.html" rel="external">"Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Supportive therapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Red blood cell transfusions for anemia when clinically indicated (eg, hemoglobin level reaches 6 to 7 g/dL or hematocrit &lt;18 percent).</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet transfusion for patients who have significant clinical bleeding.</p><p class="bulletIndent1"><span class="glyph">●</span>Appropriate fluid and electrolyte management to maintain adequate intravascular volume and correct/avoid electrolyte abnormalities.</p><p class="bulletIndent1"><span class="glyph">●</span>Stopping nephrotoxic drugs or those that are implicated in the etiology of HUS.</p><p class="bulletIndent1"><span class="glyph">●</span>Initiation of dialysis therapy in patients with symptomatic uremia, azotemia (defined as a blood urea nitrogen &gt;80 mg/dL [29 mmol/L]), severe fluid overload, or electrolyte abnormality that is refractory to medical therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>Provision of adequate nutrition.</p><p></p><p class="headingAnchor" id="H2115551903"><span class="h2">Additional measures</span><span class="headingEndMark"> — </span>The use of other interventions is dependent on the underlying cause of HUS and is discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>STEC HUS (see  <a class="medical medical_review" href="/z/d/html/6097.html" rel="external">"Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Directed intervention for STEC-hemolytic uremic syndrome'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Complement-mediated HUS (see  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Treatment'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumococcal-associated HUS (see <a class="local">'Management'</a> above)</p><p></p><p class="headingAnchor" id="H51354281"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117977.html" rel="external">"Society guideline links: Hemolytic uremic syndrome in children"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/117846.html" rel="external">"Society guideline links: Thrombotic microangiopathies (TTP, HUS, and related disorders)"</a>.)f</p><p class="headingAnchor" id="H12590760"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Hemolytic uremic syndrome (HUS) is defined by the concurrent characteristic triad of HUS: microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Although all pediatric cases exhibit the classic triad of findings that define HUS, there are a number of various etiologies of HUS that result in differences in presentation, management, and outcome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification </strong>– A classification system is used to describe the different etiologies of HUS and is divided into primary and secondary causes. (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary causes</strong> include disorders that result in complement dysregulation and rarely mutations of proteins in the coagulation pathway and cobalamin metabolism (See <a class="local">'Hereditary HUS'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Complement-mediated HUS</strong> accounts for 5 to 10 percent of HUS pediatric cases and is primarily due to mutations in the genes for complement proteins C3, CD46 (previously known as membrane cofactor protein [MCP]), and complement factors H, I, and B. The clinical manifestations, diagnosis, evaluation, and management of complement-mediated HUS are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Genetic variants'</a> and  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Complement antibodies'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secondary causes</strong> include infectious etiologies (eg, Shiga toxin-producing Escherichia coli [STEC] and Pneumococcus). Other rare causes include antibody formation due to complement proteins, drug toxicity in pediatric solid organ recipients and children with cancer; adverse effect of <a class="drug drug_pediatric" data-topicid="12756" href="/z/d/drug information/12756.html" rel="external">quinine</a>, and oral contraceptives; and complications seen in patients with systemic lupus erythematosus and antiphospholipid syndrome, or pregnancy. (See <a class="local">'Acquired infectious-induced HUS'</a> above and <a class="local">'Acquired non-infectious causes'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Shiga toxin-producing Escherichia coli (STEC) HUS</strong> accounts for over 90 percent of pediatric HUS cases. It is generally preceded by a prodromal illness with abdominal pain, vomiting, and diarrhea  (<a class="graphic graphic_figure graphicRef75352" href="/z/d/graphic/75352.html" rel="external">figure 1</a>). The clinical manifestations, diagnosis, evaluation, and management of STEC-HUS are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">"Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"</a> and  <a class="medical medical_review" href="/z/d/html/6097.html" rel="external">"Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Pneumococcal-associated HUS</strong> is the second most common infectious cause of HUS. It occurs mainly in young children and infants who usually present with pneumonia. Most patients undergo dialysis treatment, and extra-renal complications are common. There is approximately a 10 percent mortality rate, and another 10 percent of patients with pneumococcal-associated HUS progress to end-stage kidney disease (ESKD). (See <a class="local">'Streptococcus pneumoniae'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of HUS is clinically based on the presence of the classical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. The diagnosis is established by laboratory tests that include a complete blood count (eg, hemoglobin/hematocrit and platelet count) and peripheral blood smear, renal functions studies (serum creatinine), and urinalysis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis for HUS includes conditions that present with concomitant findings of anemia, thrombocytopenia, and acute kidney injury. These include disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, and inborn errors of vitamin B12. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Further evaluation is needed to determine the underlying cause of HUS and to differentiate HUS from other disorders. (See <a class="local">'Evaluation to identify underlying etiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>History</strong> – Historical clues are useful in suggesting STEC disease (history of STEC exposure or concurrent episode of HUS in family member), complement-mediated HUS (noncurrent family history of HUS or previous history of HUS), or a secondary cause (eg, history of a predisposing medical condition or drug).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory testing</strong> – Additional laboratory studies include coagulation studies, screening for STEC, cultures of blood and other pertinent bodily fluids, complement studies, and cobalamin studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supportive care</strong> – The following supportive measures are provided to all children with HUS based on observational data from studies of patients with STEC-HUS (See <a class="local">'Supportive care'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Red blood cell transfusions for anemia when the hemoglobin level reaches 6 to 7 g/dL or hematocrit &lt;18 percent. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Platelet transfusion for patients who have significant clinical bleeding or if an invasive procedure is required.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Appropriate fluid and electrolyte management to maintain adequate intravascular volume and correct/avoid electrolyte abnormalities.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Stopping nephrotoxic drugs or those that are implicated in the etiology of HUS.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Initiation of kidney replacement therapy in patients with symptomatic uremia, azotemia (defined as a blood urea nitrogen &gt;80 mg/dL [29 mmol/L]), severe fluid overload, or electrolyte abnormality that is refractory to medical therapy. (See  <a class="medical medical_review" href="/z/d/html/15895.html" rel="external">"Pediatric acute kidney injury: Indications, timing, and choice of modality for kidney replacement therapy"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Provision of adequate nutrition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional measures</strong> – The use of additional interventions is dependent on the underlying cause of HUS. (See <a class="local">'Additional measures'</a> above.).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>STEC HUS. (See  <a class="medical medical_review" href="/z/d/html/6097.html" rel="external">"Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Directed intervention for STEC-hemolytic uremic syndrome'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complement-mediated HUS. (See  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pneumococcal-associated HUS – We suggest initial empiric antibiotic therapy in patients with pneumococcal-associated HUS (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Due to the increasing prevalence of antibiotic-resistant strains of pneumococcus, we suggest that coverage should include both <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> and a broad-spectrum cephalosporins (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> or <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a>) while awaiting culture results and sensitivities (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Management'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16:1035.</a></li><li><a class="nounderline abstract_t">Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017; 91:539.</a></li><li><a class="nounderline abstract_t">Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017; 390:681.</a></li><li><a class="nounderline abstract_t">Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J 2019; 12:333.</a></li><li><a class="nounderline abstract_t">Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016; 31:15.</a></li><li><a class="nounderline abstract_t">Ardissino G, Salardi S, Colombo E, et al. Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network. Eur J Pediatr 2016; 175:465.</a></li><li><a class="nounderline abstract_t">Taylor CM, Machin S, Wigmore SJ, et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010; 148:37.</a></li><li><a class="nounderline abstract_t">Constantinescu AR, Bitzan M, Weiss LS, et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis 2004; 43:976.</a></li><li><a class="nounderline abstract_t">Waters AM, Kerecuk L, Luk D, et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United kingdom experience. J Pediatr 2007; 151:140.</a></li><li><a class="nounderline abstract_t">Noris M, Remuzzi G. Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management? Nat Clin Pract Nephrol 2005; 1:2.</a></li><li><a class="nounderline abstract_t">Geerdink LM, Westra D, van Wijk JA, et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 2012; 27:1283.</a></li><li><a class="nounderline abstract_t">Lemaire M, Frémeaux-Bacchi V, Schaefer F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013; 45:531.</a></li><li><a class="nounderline abstract_t">Westland R, Bodria M, Carrea A, et al. Phenotypic expansion of DGKE-associated diseases. J Am Soc Nephrol 2014; 25:1408.</a></li><li><a class="nounderline abstract_t">Sánchez Chinchilla D, Pinto S, Hoppe B, et al. Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2014; 9:1611.</a></li><li><a class="nounderline abstract_t">Bu F, Maga T, Meyer NC, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014; 25:55.</a></li><li><a class="nounderline abstract_t">Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:345.</a></li><li><a class="nounderline abstract_t">Ogier de Baulny H, Gérard M, Saudubray JM, Zittoun J. Remethylation defects: guidelines for clinical diagnosis and treatment. Eur J Pediatr 1998; 157 Suppl 2:S77.</a></li><li><a class="nounderline abstract_t">Beck BB, van Spronsen F, Diepstra A, et al. Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity. Pediatr Nephrol 2017; 32:733.</a></li><li><a class="nounderline abstract_t">Kind T, Levy J, Lee M, et al. Cobalamin C disease presenting as hemolytic-uremic syndrome in the neonatal period. J Pediatr Hematol Oncol 2002; 24:327.</a></li><li><a class="nounderline abstract_t">Sharma AP, Greenberg CR, Prasad AN, Prasad C. Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder. Pediatr Nephrol 2007; 22:2097.</a></li><li><a class="nounderline abstract_t">Guigonis V, Frémeaux-Bacchi V, Giraudier S, et al. Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation. Am J Kidney Dis 2005; 45:588.</a></li><li><a class="nounderline abstract_t">Van Hove JL, Van Damme-Lombaerts R, Grünewald S, et al. Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy. Am J Med Genet 2002; 111:195.</a></li><li><a class="nounderline abstract_t">Fischer S, Huemer M, Baumgartner M, et al. Clinical presentation and outcome in a series of 88 patients with the cblC defect. J Inherit Metab Dis 2014; 37:831.</a></li><li><a class="nounderline abstract_t">Menni F, Testa S, Guez S, et al. Neonatal atypical hemolytic uremic syndrome due to methylmalonic aciduria and homocystinuria. Pediatr Nephrol 2012; 27:1401.</a></li><li><a class="nounderline abstract_t">Carrillo-Carrasco N, Chandler RJ, Venditti CP. Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management. J Inherit Metab Dis 2012; 35:91.</a></li><li><a class="nounderline abstract_t">Veesenmeyer AF, Edmonson MB. Trends in US hospital stays for Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Infect Dis J 2013; 32:731.</a></li><li><a class="nounderline abstract_t">Copelovitch L, Kaplan BS. Streptococcus pneumoniae--associated hemolytic uremic syndrome: classification and the emergence of serotype 19A. Pediatrics 2010; 125:e174.</a></li><li><a class="nounderline abstract_t">Lawrence J, Gwee A, Quinlan C. Pneumococcal haemolytic uraemic syndrome in the postvaccine era. Arch Dis Child 2018; 103:957.</a></li><li><a class="nounderline abstract_t">Makwana A, Sheppard C, Fry NK, Ladhani SN. Pneumococcal-related Hemolytic Uremic Syndrome in the United Kingdom: National Surveillance, 2006-2016. Pediatr Infect Dis J 2019; 38:e254.</a></li><li><a class="nounderline abstract_t">Scobell RR, Kaplan BS, Copelovitch L. New insights into the pathogenesis of Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol 2020; 35:1585.</a></li><li><a class="nounderline abstract_t">Meinel C, Spartà G, Dahse HM, et al. Streptococcus pneumoniae From Patients With Hemolytic Uremic Syndrome Binds Human Plasminogen via the Surface Protein PspC and Uses Plasmin to Damage Human Endothelial Cells. J Infect Dis 2018; 217:358.</a></li><li><a class="nounderline abstract_t">Szilágyi A, Kiss N, Bereczki C, et al. The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2013; 28:2237.</a></li><li><a class="nounderline abstract_t">Holle J, Habbig S, Gratopp A, et al. Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome. Pediatr Nephrol 2021; 36:1311.</a></li><li><a class="nounderline abstract_t">Geary DF. Hemolytic uremic syndrome and streptococcus pneumoniae: improving our understanding. J Pediatr 2007; 151:113.</a></li><li><a class="nounderline abstract_t">Huang DT, Chi H, Lee HC, et al. T-antigen activation for prediction of pneumococcus-induced hemolytic uremic syndrome and hemolytic anemia. Pediatr Infect Dis J 2006; 25:608.</a></li><li><a class="nounderline abstract_t">Banerjee R, Hersh AL, Newland J, et al. Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America. Pediatr Infect Dis J 2011; 30:736.</a></li><li><a class="nounderline abstract_t">Copelovitch L, Kaplan BS. Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol 2008; 23:1951.</a></li><li><a class="nounderline abstract_t">Spinale JM, Ruebner RL, Kaplan BS, Copelovitch L. Update on Streptococcus pneumoniae associated hemolytic uremic syndrome. Curr Opin Pediatr 2013; 25:203.</a></li><li><a class="nounderline abstract_t">Turner ME, Kher K, Rakusan T, et al. A typical hemolytic uremic syndrome in human immunodeficiency virus-1-infected children. Pediatr Nephrol 1997; 11:161.</a></li><li><a class="nounderline abstract_t">Caltik A, Akyüz SG, Erdogan O, Demircin G. Hemolytic uremic syndrome triggered with a new pandemic virus: influenza A (H1N1). Pediatr Nephrol 2011; 26:147.</a></li><li><a class="nounderline abstract_t">Golubovic E, Miljkovic P, Zivic S, et al. Hemolytic uremic syndrome associated with novel influenza A H1N1 infection. Pediatr Nephrol 2011; 26:149.</a></li><li><a class="nounderline abstract_t">Rhee H, Song SH, Lee YJ, et al. Pandemic H1N1 influenza A viral infection complicated by atypical hemolytic uremic syndrome and diffuse alveolar hemorrhage. Clin Exp Nephrol 2011; 15:948.</a></li><li><a class="nounderline abstract_t">Trachtman H, Sethna C, Epstein R, et al. Atypical hemolytic uremic syndrome associated with H1N1 influenza A virus infection. Pediatr Nephrol 2011; 26:145.</a></li><li><a class="nounderline abstract_t">Allen U, Licht C. Pandemic H1N1 influenza A infection and (atypical) HUS--more than just another trigger? Pediatr Nephrol 2011; 26:3.</a></li><li><a class="nounderline abstract_t">Bento D, Mapril J, Rocha C, et al. Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1). Ren Fail 2010; 32:753.</a></li><li><a class="nounderline abstract_t">Watanabe T. Renal complications of seasonal and pandemic influenza A virus infections. Eur J Pediatr 2013; 172:15.</a></li><li><a class="nounderline abstract_t">Printza N, Roilides E, Kotsiou M, et al. Pandemic influenza A (H1N1) 2009-associated hemolytic uremic syndrome. Pediatr Nephrol 2011; 26:143.</a></li><li><a class="nounderline abstract_t">Bitzan M, Zieg J. Influenza-associated thrombotic microangiopathies. Pediatr Nephrol 2018; 33:2009.</a></li><li><a class="nounderline abstract_t">Lei TH, Hsia SH, Wu CT, Lin JJ. Streptococcus pneumoniae-associated haemolytic uremic syndrome following influenza A virus infection. Eur J Pediatr 2010; 169:237.</a></li><li><a class="nounderline abstract_t">Al-Akash SI, Almond PS, Savell VH Jr, et al. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 2011; 26:613.</a></li><li><a class="nounderline abstract_t">Cavagnaro F, Guzmán C, Harris P. Hemolytic uremic syndrome associated with Entamoeba histolytica intestinal infection. Pediatr Nephrol 2006; 21:126.</a></li><li><a class="nounderline abstract_t">Godron A, Pereyre S, Monet C, et al. Hemolytic uremic syndrome complicating Mycoplasma pneumoniae infection. Pediatr Nephrol 2013; 28:2057.</a></li><li class="breakAll">Noris M, Bresin E, Mele C et al. Atypical Hemoltyic-Uremic Syndrome. GeneReviews. http://www.ncbi.nlm.nih.gov/books/NBK1367/ (Accessed on April 15, 2013).</li><li><a class="nounderline abstract_t">Jodele S, Davies SM, Lane A, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014; 124:645.</a></li><li><a class="nounderline abstract_t">Seaby EG, Gilbert RD. Thrombotic microangiopathy following haematopoietic stem cell transplant. Pediatr Nephrol 2018; 33:1489.</a></li><li><a class="nounderline abstract_t">Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129.</a></li><li><a class="nounderline abstract_t">Bruel A, Kavanagh D, Noris M, et al. Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Clin J Am Soc Nephrol 2017; 12:1237.</a></li><li><a class="nounderline abstract_t">Huerta A, Arjona E, Portoles J, et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int 2018; 93:450.</a></li><li><a class="nounderline abstract_t">Gupta M, Govindappagari S, Burwick RM. Pregnancy-Associated Atypical Hemolytic Uremic Syndrome: A Systematic Review. Obstet Gynecol 2020; 135:46.</a></li><li><a class="nounderline abstract_t">Fakhouri F. Pregnancy-related thrombotic microangiopathies: Clues from complement biology. Transfus Apher Sci 2016; 54:199.</a></li><li class="breakAll">Habib R. Pathology of the hemolytic uremic syndrome. In: Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura, Kaplan B, Trompeter R, Moake J (Eds), Marcel Dekker, New York 1992. p.315.</li></ol></div><div id="topicVersionRevision">Topic 89549 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728781" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27989322" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28242109" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31198225" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25859752" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : An international consensus approach to the management of atypical hemolytic uremic syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26498648" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821824" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15168377" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Non-enteropathic hemolytic uremic syndrome: causes and short-term course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17643764" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United kingdom experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16932353" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22410797" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23542698" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24511134" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Phenotypic expansion of DGKE-associated diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25135762" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24029428" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19625716" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Thrombomodulin mutations in atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9587031" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Remethylation defects: guidelines for clinical diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27289364" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11972107" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cobalamin C disease presenting as hemolytic-uremic syndrome in the neonatal period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17874135" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15754282" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12210350" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24599607" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical presentation and outcome in a series of 88 patients with the cblC defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22447314" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neonatal atypical hemolytic uremic syndrome due to methylmalonic aciduria and homocystinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21748409" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23838775" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Trends in US hospital stays for Streptococcus pneumoniae-associated hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20026500" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Streptococcus pneumoniae--associated hemolytic uremic syndrome: classification and the emergence of serotype 19A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29674516" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pneumococcal haemolytic uraemic syndrome in the postvaccine era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31232894" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pneumococcal-related Hemolytic Uremic Syndrome in the United Kingdom: National Surveillance, 2006-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31515631" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : New insights into the pathogenesis of Streptococcus pneumoniae-associated hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28968817" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Streptococcus pneumoniae From Patients With Hemolytic Uremic Syndrome Binds Human Plasminogen via the Surface Protein PspC and Uses Plasmin to Damage Human Endothelial Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23787556" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33538911" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17643758" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hemolytic uremic syndrome and streptococcus pneumoniae: improving our understanding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16804430" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : T-antigen activation for prediction of pneumococcus-induced hemolytic uremic syndrome and hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21772230" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17564729" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Streptococcus pneumoniae-associated hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23481474" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Update on Streptococcus pneumoniae associated hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9090654" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A typical hemolytic uremic syndrome in human immunodeficiency virus-1-infected children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20878189" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hemolytic uremic syndrome triggered with a new pandemic virus: influenza A (H1N1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21076984" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hemolytic uremic syndrome associated with novel influenza A H1N1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21826588" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pandemic H1N1 influenza A viral infection complicated by atypical hemolytic uremic syndrome and diffuse alveolar hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20803299" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Atypical hemolytic uremic syndrome associated with H1N1 influenza A virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21057815" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pandemic H1N1 influenza A infection and (atypical) HUS--more than just another trigger?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20540647" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23064728" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Renal complications of seasonal and pandemic influenza A virus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628763" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pandemic influenza A (H1N1) 2009-associated hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28884355" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Influenza-associated thrombotic microangiopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19908065" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Streptococcus pneumoniae-associated haemolytic uremic syndrome following influenza A virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21125405" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16222550" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hemolytic uremic syndrome associated with Entamoeba histolytica intestinal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23800801" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hemolytic uremic syndrome complicating Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23800801" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hemolytic uremic syndrome complicating Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24876561" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28993886" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Thrombotic microangiopathy following haematopoietic stem cell transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337603" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : VEGF inhibition and renal thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28596415" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hemolytic Uremic Syndrome in Pregnancy and Postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28911789" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31809447" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pregnancy-Associated Atypical Hemolytic Uremic Syndrome: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27158062" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pregnancy-related thrombotic microangiopathies: Clues from complement biology.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
